Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Biopharmaceutical company Xenon Pharmaceuticals Inc. detracted from performance after voluntarily pausing enrollment of new patients in its Phase 3 depression studies following the emergence of neuropsychiatric adverse events, including confusion, somnolence, ataxia, and rare cases of psychosis. The announcement was...
— Neal Kaufman
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Xenon Pharmaceuticals Inc.
No other institutional pitches found for this ticker yet.
More institutional theses from Baron Health Care Fund
Eli Lilly and Company ($LLY) is a global pharmaceutical leader specializing in treatments for diabetes, obesity, oncology, and immunology, representing the Fund's largest portfolio holding at 14.3% of net assets. The manager maintains...
Thermo Fisher Scientific Inc. ($TMO) is the world's premier provider of life sciences tools, laboratory supplies, analytical instruments, and clinical trial services, representing 5.9% of fund assets. The investment manager...
Mettler-Toledo International Inc. ($MTD) manufactures precision laboratory balances, analytical instruments, and industrial inspection systems essential for research and quality assurance, comprising 7.5% of fund assets. The manager holds...